Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Izotropic ( (TSE:IZO) ) has issued an update.
Izotropic closed a $300,000 non-brokered private placement by issuing 1.2 million units priced at $0.25, each carrying a share and three-year warrant, with proceeds earmarked for general working capital and contingent on regulatory approvals; it also plans to settle $60,000 of accrued interest on a 2022 promissory note by issuing 240,000 settlement units with identical pricing and warrant terms, pending Canadian Securities Exchange approval.
The most recent analyst rating on (TSE:IZO) stock is a Sell with a C$0.23 price target. To see the full list of analyst forecasts on Izotropic stock, see the TSE:IZO Stock Forecast page.
Spark’s Take on TSE:IZO Stock
According to Spark, TipRanks’ AI Analyst, TSE:IZO is a Neutral.
The score is primarily constrained by very weak financial performance (no revenue, persistent losses, ongoing cash burn, and negative equity), which outweighs other considerations. Technicals add further pressure (below key moving averages with negative MACD), and valuation provides limited support due to loss-making earnings and no dividend yield.
To see Spark’s full report on TSE:IZO stock, click here.
More about Izotropic
Izotropic is a medical device company developing imaging technologies aimed at improving the accuracy of breast cancer screening, diagnosis, and treatment, positioning itself within the medical imaging segment of the oncology care market.
Average Trading Volume: 38,147
Technical Sentiment Signal: Sell
Current Market Cap: C$16.27M
For an in-depth examination of IZO stock, go to TipRanks’ Overview page.